Drug Trial Radar · NCT07556471
Evaluation of the Efficacy and Safety of LW402 Tablets in Patients With Non-Segmental Vitiligo
Last checked: Nov 19, 2026Latest source record: Apr 29, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
180
Planned (sponsor's estimate)
Start
May 31, 2026
Primary completion
Feb 1, 2028
Study completion Dec 31, 2028
Sponsor
- Lead sponsor
- Shanghai Longwood Biopharmaceuticals Co., Ltd.Industry
- Sponsor type
- Industry
- Collaborators
- Clinical Service, China
- First posted
- Apr 29, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a multicenter, randomized, double-blind, placebo-controlled Phase II clinical trial designed to assess the efficacy, safety, and tolerability of LW402 tablets in participants with non-segmental vitiligo. Drawing on the prior/preclinical data of LW402 tablets, this clinical trial will incorporate three dose groups: 50 mg twice daily (BID), 100 mg BID, and 150 mg BID. The trial will be structured into a screening period (maximum 5 weeks), a treatment period (52 weeks, encompassing a 24-week main trial phase and a 28-week extension phase), and a safety follow-up period (4 weeks). The maximum duration of participation in this study will be 61 weeks. Following the completion of 24-week data collection for all trial participants, unblinding will be performed in accordance with the pre-specified procedure. Subsequently, based on the unblinded data results, regulatory communication will be conducted with the Center for Drug Evaluation (CDE) regarding the initiation of the Phase III confirmatory clinical trial. Participants who have undergone unblinding will continue to attend scheduled study visits to complete the trial.
Conditions
- Non-Segmental Vitiligo (NSV)
Interventions
Experimental LW402 TabletDrug
LW402 Tablets
PlaceboDrug
LW402 Placebo Tablets
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage change in F-VASI at Week 24 relative to baselineTime frame: Baseline to Week 24
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.